Insights / Resource Center
Resources
Events
PEGS Boston Summit 2026
May 11-15, Primrose Bio presents and exhibits at the PEGS, Boston, MA.
World Vaccine Congress 2026
March 30-April 2, Primrose Bio presented and exhibited at the WVC, Washington.
5th Annual Novel Conjugates Summit 2026
March 17-19, Primrose Bio exhibited at the Novel Conjugates Summit, Boston, MA.
Presentations & Webinars
Scientific Posters
Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development
ABSTRACT: Efficient production of vaccine carrier proteins and antigens is paramount to ensuring access to affordable conjugate vaccines. Streamlined conjugation technologies improve product quality...
Presented at the BioProcess International US West (BPI West) 2026: Engineered Fusion Partners Enabling HighYield Recombinant Peptide Production
ABSTRACT: Peptide therapeutics are a fast-growing class of medicines, but traditional solid phase peptide synthesis (SPPS) has limitations in cost, scalability, and environmental impact. Pfenex...
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an...
Case Studies
Pfenex
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma most often seen in teenagers and young adults.
Pfenex
Production of disulfide-rich cow knob domain antibodies: picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Pfenex
Multimeric vhh nanobody expression
Pfenex
Fab antibody fragment titer improvement
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides (peptides #5, #6, and #7) directed to one therapeutic target were conjugated to either CRM197 (a non-toxic diphtheria toxin mutant) produced with Pfenex Expression Technology® or to KLH (keyhole limpet hemocyanin).
Success Stories
Manufacturing of RYLAZE utilizes Pfenex Expression Technology
Hear from the senior director for the biologics development team at Jazz Pharmaceuticals about the RYLAZE manufacturing process.